AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
A Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Group 2
Phase 2
Active, not recruiting
- Conditions
- Pulmonary Hypertension (World Health Organization Group 2)Heart Failure
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-02-21
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 260
- Registration Number
- NCT05737940
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Patient-Reported Outcomes of Benralizumab in Real-World Use in Severe Eosinophilic Asthma Patients in Taiwan (BEAT)
Completed
- Conditions
- Asthma
- First Posted Date
- 2023-02-17
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 43
- Registration Number
- NCT05734339
- Locations
- 🇨🇳
Research Site, Taoyuan City, Taiwan
TEZSPIRE (Tezepelumab) Asthma Japan Post-Marketing Study (PMS)
Recruiting
- Conditions
- Bronchial Asthma (Only the Patients With Severe or Intractable Bronchial Asthma Which Could Not be Controlled With the Existing Therapy)
- First Posted Date
- 2023-02-15
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 400
- Registration Number
- NCT05729711
- Locations
- 🇯🇵
Research Site, Yamanashi, Japan
Multiple Dose Study of Safety and Pharmacokinetics of MEDI0618 in Healthy Volunteers
- First Posted Date
- 2023-02-06
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 36
- Registration Number
- NCT05714254
- Locations
- 🇩🇪
Research Site, Berlin, Germany
eVusheld Assessment reaL wORld Effectiveness in Israel Clalit Health Services
- First Posted Date
- 2023-02-03
- Last Posted Date
- 2025-01-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 4000
- Registration Number
- NCT05712096
- Locations
- 🇮🇱
Research Site, Ramat Gan, Israel
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Phase 2
Recruiting
- Conditions
- Gastric Cancer
- Interventions
- First Posted Date
- 2023-01-27
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 240
- Registration Number
- NCT05702229
- Locations
- 🇬🇧
Research Site, Oxford, United Kingdom
Effectiveness of the Oxford-AstraZeneca COVID-19 Vaccine as a 2nd Booster, the REFORCO-Brazil Study
Completed
- Conditions
- COVID-19
- Interventions
- Other: ChAdOx1 nCOV-19 vaccine (Vaxzeria)Other: BNT162b2 (Pfizer)Other: Ad26.COV2.S (Janssen)Other: CoronaVac (Sinovac)
- First Posted Date
- 2023-01-26
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 188814085
- Registration Number
- NCT05697705
- Locations
- 🇧🇷
Techtrials Pesquisa e Tecnologia Ltda., São Paulo, Brazil
A Study to Assess Safety, Tolerability, and Pharmacokinetics of AZD0186
- First Posted Date
- 2023-01-23
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 31
- Registration Number
- NCT05694741
- Locations
- 🇺🇸
Research Site, Glendale, California, United States
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)
- First Posted Date
- 2023-01-20
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 200
- Registration Number
- NCT05692180
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
Phase 3
Active, not recruiting
- Conditions
- NSCLC
- Interventions
- First Posted Date
- 2023-01-18
- Last Posted Date
- 2025-01-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1350
- Registration Number
- NCT05687266
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
© Copyright 2025. All Rights Reserved by MedPath